Professional Documents
Culture Documents
DH 308 – Class 6
21st January 2023
Clinical Data
Management
- Nirmal Punjabi, Ph.D.
21-01-2023 2
DH308: NIRMAL PUNJABI
Clinical Data
Planning
Why Clinical Data planning?
• In perspective of clinical trials
• Deciding factor
• Product/therapy: Useful or Junk?
• Regulatory
• Enter different geographies
• Cost Involved
• Investment on clinical trials to generate data
• Marketing
• Promotion
• Legal
• Defense against accusation of credibility
4
DH308: NIRMAL PUNJABI
21-01-2023 5
Clinical Data Planning
• Individuals involved
• Doctors/Researchers
• Biostatistician
• Clinical Data Manager
• Ethics committee members
• …….
6
Clinical Data planning
• Why data should be collected?
• What data will be collected?
• How data will be collected?
• How data will be processed?
• How data will be stored/protected/archived/destroyed?
7
Clinical Data Planning
• Begin with the process/end in mind
• What is the aim of the study?
• What factors should be controlled?
• Confounding / Interfering factors
• Real-world challenges
• Limited access to electricity
• Limited access to digital tools
• Error in noting data
• Seasonal effects
• Sharing challenges
Results &
Background Aim/Objective Background Methods/Setup Observation Conclusion
Discussion
13
Clinical Data Planning
Hypothesis OR Research Question
• PICOT is applicable to both.
• Hypothesis is statement
• Research Question is a question?
• Example:
• Is Dexamethasone more effective than placebo as an adjuvant treatment to improve
oxygen saturation levels within 14 days in hospitalized covid-19 positive patients who
have had curative treatment for cancer?
• Dexamethasone is more effective than placebo as an adjuvant treatment to improve
oxygen saturation levels within 14 days in hospitalized covid-19 positive patients who
have had curative treatment for cancer.
14
Clinical Data Planning
Practical Scenario:
• Literature will have mix of Hypothesis or Research Question
• Many literature will not completely follow the PICOT rule.
• PICO is seen in many literature
• PIO is also observed.
• ‘C’ is assumed to be placebo or standard care
15
Clinical Data Planning
What all should be planned? & Dependencies
• Regulatory requirements
• Country specific
• Protection of patient identity
• Standard format for storage of data
17
Basics
Diabetes
• Problems with glucose
management
• Type II
• Insulin is less or ineffective (resistant)
• Prevalent: 90 to 95%
• Medication: Insulin + Medicines
• Gestational Diabetes
• Developed during pregnancy
Diabetes
• Need for regular monitoring
• Track the glucose changes
with activity
• Meals
• Lifestyle
• Medicine Intake
• Improve Treatment
• Optimize Insulin / medicine
dose
• Reduce/Delay Complications
• Loss of vision
• Kidney failure
• Amputation
• …….
Image Reference: http://www.xlab.ro/en/Glycosylated-hemoglobin-assay/; Fig 15.9 from Essentials of Human Anatomy & Physiology, 13th Edition, Elaine N. Marieb and 21
21-01-2023 Suzanne M. Keller
Basics
Diabetes
• What can be monitored?
• Blood Glucose
✓ Gold Standard
× Pricking: Pain / Swelling
• Glycosylated hemoglobin
✓ Average blood glucose levels
over 3 months
× Averaging: No data of short
term
× Not reliable: Anemia,
Pregnancy and blood disorders